$1.16
Today
as of Sep 4, 16:53 ET
Last 30 days
Recent Press Releases & News
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
Overview
52-week range
$1.02
$1.95
15% of range
Avg surprise (last 3)
-9.8%
Avg reaction (last 2)
+0.2%
50% positive
Latest IV / EM
1490%
EM ±232.8% · $3 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.36 | — | — | — | — | financials |
| Mon May 11, 2026 | Mar/2026 | $-0.32 | $-0.36 | +11.1% | +65.2% | -1.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.43 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.71 | $-0.62 | -14.5% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.92 | $-0.73 | -26.0% | — | +2.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.95 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.92 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.78 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.70 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.70 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.67 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-24M | $-22M | — | $-28M | $-46M | $-59M | — | $-62M |
| Net income | $-22M | $-20M | — | $-26M | $-43M | $-56M | — | $-58M |
| EPS (diluted) | $-0.36 | $-0.32 | — | $-0.43 | $-0.71 | $-0.92 | — | $-0.95 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $25M | $22M | $45M | $94M | $87M | $92M | $71M | $80M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $163M | $175M | $196M | $246M | $267M | $311M | $362M | $410M |
| Total assets | $190M | $203M | $225M | $277M | $300M | $345M | $397M | $446M |
| Long-term debt | $0 | $0 | $0 | $30M | $30M | $30M | $30M | $30M |
| Total liabilities | $43M | $37M | $44M | $76M | $80M | $88M | $93M | $100M |
| Total equity | $147M | $165M | $181M | $200M | $220M | $257M | $304M | $346M |